Pull to refresh
Logo
Talazoparib trial moves a targeted prostate cancer drug to an earlier stage

Talazoparib trial moves a targeted prostate cancer drug to an earlier stage

New Capabilities

Final TALAPRO-3 results back a pending FDA review of the Talzenna-Xtandi combination for men with inherited DNA-repair mutations

Yesterday: Final results published in the New England Journal of Medicine

Overview

About one in four men with advanced prostate cancer carry inherited flaws in the genes that repair damaged DNA. A large trial now shows that giving those men a targeted pill alongside standard hormone therapy delays the cancer's spread by a wide margin.

The New England Journal of Medicine published the final TALAPRO-3 results on July 30, 2026. The data support a pending U.S. approval that would push the drug into an earlier, more treatable stage of the disease.

Why it matters

For the roughly one in four advanced prostate cancer patients with these DNA-repair mutations, adding one pill more than halved the risk of the cancer spreading.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

52%
Lower risk of progression or death
Adding talazoparib cut the risk of the cancer growing or the patient dying, versus hormone therapy alone.
599
Patients enrolled
Men with metastatic castration-sensitive prostate cancer carrying HRR gene mutations.
75%
Objective response rate
Share whose tumors shrank on the combination, versus 67% on hormone therapy alone.
51%
Severe anemia
Grade 3 or higher anemia in the talazoparib group, mostly managed by lowering the dose.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 3 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

June 2023 July 2026

4 events Latest: Yesterday
Tap a bar to jump to that date
  1. Final results published in the New England Journal of Medicine

    Latest Publication

    The NEJM publishes the full TALAPRO-3 dataset, cementing the evidence behind the pending FDA review of the combination.

  2. FDA grants priority review

    Regulatory

    The FDA accepts Pfizer's application to expand the combination into castration-sensitive disease and sets a decision date in late 2026.

  3. TALAPRO-3 results unveiled at ASCO

    Clinical Data

    Investigators report a 52% reduction in the risk of progression or death, with benefit in both BRCA and non-BRCA patients. Data were released alongside a journal publication.

  4. Combination approved for later-stage prostate cancer

    Regulatory

    The FDA clears talazoparib plus enzalutamide for HRR-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

May 2020

First PARP inhibitor approved in prostate cancer (2020)

The FDA approved olaparib for men with HRR-mutated metastatic castration-resistant prostate cancer, based on the PROfound trial. It was the first time a PARP inhibitor, a drug class born in ovarian and breast cancer, reached prostate cancer patients.

Then

Genetic testing for BRCA and related mutations became routine in advanced prostate cancer.

Now

It opened the door to PARP inhibitor combinations that later moved the class earlier in treatment.

Why this matters now

TALAPRO-3 continues that push, testing whether the same biology helps men at an earlier, hormone-sensitive stage.

2023

PARP-plus-hormone combinations reach castration-resistant disease (2023)

The FDA approved three PARP inhibitor and hormone-therapy combinations for castration-resistant prostate cancer, including talazoparib with enzalutamide. But it restricted some of them to BRCA-mutated patients rather than the full HRR group.

Then

Oncologists gained new options but had to match each drug to a specific mutation profile.

Now

The BRCA-versus-HRR labeling debate became the central regulatory question for the class.

Why this matters now

It shows why a TALAPRO-3 approval could still come with a narrower label than the trial population.

September 1998

Trastuzumab and the biomarker-drug model (1998)

The FDA approved trastuzumab for breast cancers that overexpress the HER2 protein, paired with a companion test. It tied a drug's use to a specific genetic feature of the tumor for the first time at scale.

Then

HER2 testing became standard, sorting patients into those likely to benefit and those unlikely to.

Now

It set the template for precision oncology: test first, then treat the matched subgroup.

Why this matters now

TALAPRO-3 follows that model, giving the drug only to men whose tumors carry the targeted DNA-repair mutations.

Sources

(4)